Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Empresa
Empresa
Nuestra historia
Nuestro equipo
Carreras
Socios
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Acceso
Asuntos médicos
Acceso de pacientes
Póngase en contacto con Asuntos Médicos
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Recursos
Recursos
En las noticias
Comunicados de prensa
Recursos para pacientes
Preguntas frecuentes
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Inversores
Inversores
Descripción general del inversor
Información financiera
Eventos
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors.
AIDM
AI Powered Drug Discovery and Manufacturing (AIDM)
June 2, 2022
,
Pabla, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Poster
QS-21 STIMULON™ Adjuvant
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria. RTS,S Malaria Vaccine Evaluation Group.
Other Articles & Publications
New England Journal of Medicine
June 2, 2022
,
Stoute, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
Three Double-Blind, Randomized Trials Evaluating the Safety and Tolerance of Different Formulations of the Saponin Adjuvant QS-21.
Other Articles & Publications
Vaccine
June 2, 2022
,
Waite, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21.